Background Sphingolipids, components of cellular membranes in eukaryotic cells, have roles in the regulation of tumor growth, inflammation, angiogenesis, and immunity. We investigated the effects of dietary glucosylceramides, sphingolipids isolated from rice bran, on tumor growth of human head and neck squamous cell carcinoma. Methods The tumor cell line SCCKN cells isolated from well-differentiated human head and neck cancer were subcutaneously inoculated into the right flank of NOD/ SCID mice, to establish an SCCKN xenograft model. Rice bran glucosylceramides (300 mg/kg/day) were administered orally to the mice for 14 consecutive days.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent neoplasm in the world. Worldwide, 500,000 patients are diagnosed with HNSCC annually [1] . The 5-year survival of patients with advanced HNSCC is less than 40% [2] .
Historically, advanced and resectable HNSCCs were treated surgically followed by postoperative radiotherapy and chemotherapy. However, these therapies resulted in significant cosmetic deformity, and functional deficits in speech and swallowing. Combined approaches have been developed during the last decades, and a chemotherapy has been confirmed as a major component of treatment to enhance loco-regional disease control, to reduce distant metastasis, and to prolong survival [3] . Cisplatin, either alone or in combination with other agents, particularly 5-fluorouracil, has, for many years, been the golden standard for HNSCC chemotherapy. Several new anticancer agents, including taxanes, ifosfamide, vinorelbine, topotecan, and gemcitabine, are now also being used in clinical practice.
Despite these treatment options, however, survival of patients with HNSCC has not been significantly improved in recent decades [1, 4] . Furthermore, chemotherapy and radiotherapy are not innocuous, being accompanied by substantial morbidity including radionecrosis, tissue fibrosis, mucosal atrophy, xerostomia, and gastrointestinal, bone marrow and renal toxicity [5] . Therefore, the development of novel strategies that reduce adverse effects and increase therapeutic benefit is needed for treatment of HNSCC.
Sphingolipids are a group of structural and functional derivatives that have a long-chain (sphingoid) base backbone and exert a variety of biological activity that mediates cell growth, differentiation, and apoptosis [6] [7] [8] [9] [10] . Ceramide, a central sphingolipid, formed in response to treatment with chemotherapeutic reagents and cell-death ligands such as Fas ligand and TNF-a, has been implicated in mediating apoptosis of cancer cells [8, 11, 12] . Moreover, treatment with exogenous ceramides has been shown to induce apoptosis in human cancer cells both in vitro and in vivo [11, 13] .
Glucosylceramide, a glycosylated form of ceramide, has been reported to have cytotoxic effects in various types of cancer cells, for example liver, skin, and lung cancer cells [14] . Interestingly, treatment with C 18:0 -glucosylceramide has been shown to inhibit the growth of lung adenocarcinoma cells but not normal cells (lung normal diploid fibroblasts) in vitro, suggesting potential anti-cell growth activity of glucosylceramides specific for tumor cells [14] . Therefore, glucosylceramide could become a potential anti-cancer agent.
Studies have shown that feeding experimental animals with sphingolipids, for example sphingomyelins and glucosylceramides, inhibits colon carcinogenesis, suggesting that sphingolipids are a functional constituent of food [15] [16] [17] [18] . Milk, eggs, and soybeans seem to be rich sources of sphingolipids, although only a limited number of foods have been analyzed chemically and biologically [9, 19] . Bran and the endoderm of rice grains have been shown to contain ceramides and glucosylceramides [20] , and feeding glucosylceramides isolated from rice bran has been reported to inhibit colon carcinogenesis [13] . No deleterious effects have yet been noted in several studies that have investigated the effects of dietary sphingolipids [18] .
Because the inhibitory effects of dietary glucosylceramides on tumor development of HNSCC were still unknown, in this study we examined whether dietary rice bran glucosylceramides had anti-tumor activity in a xenograft model of well-differentiated squamous cell carcinoma (SCCKN) cells established from human tongue cancer.
Materials and methods

Materials
Dietary glucosylceramides (1-O-b-glucosyl-N-2 0 -hydroxyarachidoyl-4,8-sphingadienine) were extracted from rice bran at the Oryza Oil and Fat Chemical Company (Aichi, Japan) [13] . The purity of the glucosylceramides was 8%. A representative chemical structure is shown in Fig. 1 . Cleaved caspase-3 antibody was from Cell Signaling Technology. Biotinylated rabbit anti-goat IgG antibody, streptavidin-horseradish peroxidase solution, and 3,3 0 -diaminobenzindiene tetrahydrochloride chromogen were from Millipore. Other reagents were obtained from Sigma (St Louis, MO).
Cell culture
The SCCKN cell line established from a well-differentiated recurrent squamous cell carcinoma of the floor of the mouth was obtained from the Division of Organ Pathology, Tottori University. SCCKN cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 100 Units/mL penicillin, and 100 lg/mL streptomycin (humidified atmosphere of 5% CO 2 /95% air at 37°C).
Animals
Male and female NOD/SCID mice (8-10 weeks of age) were obtained from a breeding colony kept at the animal experimental institute of Tottori University Hospital, Tottori. The mice were housed in a high-efficiency particulate air-filtered, positive pressure room (temperature 24 ± 2°C, 55% humidity). Tumor cell xenografts Tumor cell xenografts were obtained by subcutaneous injection of 3.0 9 10 6 cells into the left flank of NOD/ SCID mice using a 23-gauge needle. After confirmation of successful implantation (1 month after inoculation), mice were randomly divided into two groups: control (n = 8) and glucosylceramide (n = 8). We discarded mice bearing a tumor less than 7 mm in diameter. All procedures were performed in a positive-pressure room. The mice were monitored daily after treatment. The animals were euthanized when moribund. A mouse was considered moribund if it exhibited more than one of the following signs: inability to obtain food or water, loss of [20% of body weight, severe lethargy, and severe balance or gait disturbance. The protocols were approved by the Animal Research Committee of Tottori University.
Treatment
Mice were given dietary glucosylceramide (300 mg/kg) suspended in cellulose daily for 14 consecutive days by gavage, using a disposable feeding needle (0.9 9 38 mm) (Exec, Tokyo, Japan). The solution was delivered after positioning the end of the feeding tube distal to the upper esophageal sphincter to prevent aspiration of the solution during the procedure.
Tumor measurement
Tumors were measured twice a week in two dimensions using callipers. Tumor tissue volume was calculated using the formula: length 9 (width) 2 9 0.52.
Histological studies
For tumor xenograft studies, three mice per group were sacrificed 2 months after the initiation of treatment with dietary glucosylceramide. The tumors were excised, fixed for 36 h in 10% formaldehyde, and embedded in paraffin. Tissue sections (4 lm thick) were mounted on Superfrost microslides. Serial sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin. Sections were examined under an Olympus FXA upright compound microscope, and images were recorded using an Olympus digital camera under standard bright-field Kohler illumination.
TUNEL staining
Sections of tumor tissue were stained using the ApopTag plus peroxidase in-situ apoptosis detection kit (Chemicon) according to the instructions provided by the manufacturer.
Briefly, after deparaffinization and rehydration, tumor tissue sections were incubated with proteinase K for 15 min at room temperature. The slides were then rinsed with PBS and incubated with 3% H 2 O 2 in methanol for 5 min at room temperature to block endogenous peroxidase activity, followed by PBS washing and incubation in equilibration buffer for 10 s. Thereafter, sections were incubated with terminal deoxynucleotidyl transferase (TdT) in a humidified chamber at 37°C for 1 h. This was followed by washing with stop-wash buffer and incubation with anti-digoxigenin conjugate for 30 min at room temperature. After washing with PBS, the peroxidase substrate was applied followed by light counter-staining with 0.5% methyl green. The preparations were analyzed under an Olympus FXA upright compound microscope and the apoptotic index was calculated. Stained cells with a yellow-brown nucleus presenting nuclear consideration were regarded as TUNEL-positive. Apoptotic index was calculated as the percentage of TUNEL-positive cells among the total number of cells counted in 10 randomized visual fields.
Immunohistochemistry for active caspase-3 expression
Tissue sections were deparaffinized with xylene and then rehydrated with graded alcohol concentrations followed by three times washing in TBS-T. The slides were heated in 10 mM sodium citrate buffer (pH 6.0) at a sub-boiling temperature for 10 min for antigen retrieval. The specimens were washed in 25 mM Tris-buffered saline (pH 8.0) containing 0.1% Tween (PBS-T). After quenching the endogenous peroxidase activity with 3% hydrogen peroxide for 10 min, the sections were exposed to buffer A (5% normal goat serum in PBS-T) for 60 min. The sections were incubated with the primary antibody against cleaved/active caspase-3 in buffer A at 4°C overnight. The antibodies were removed, and the specimens were washed with PBS-T three times. The sections were incubated with biotinylated rabbit anti-goat IgG antibody in buffer A at room temperature for 15 min. After washing, the sections were further incubated with streptavidin-peroxidase solution at room temperature for 15 min. Finally, the sections were treated with 3,3 0 -diaminobenzindiene tetrahydrochloride chromogen followed by light counterstaining with hematoxylin. The preparations were observed with an Olympus FXA upright compound microscope. Scoring of cleaved/active caspase-3-positive cells was undertaken on 8 random fields of view from each slide by two independent observers, and the positive cells were expressed as a percentage of total cells.
Statistical analysis
All values are presented as the mean ± SD, and statistical analyses were performed using a standard t test.
Results
Inhibition of HNSCC tumor growth by dietary glucosylceramides in a xenograft model
To evaluate the effects of dietary glucosylceramides on the growth of HNSCC tumor in vivo, the maximum tolerated dose was at first determined by pharmacokinetic studies in Slc mice. First, overall toxicity was determined on the basis of viability, blood tests, including blood counts and biochemical tests, and histopathological examination of tissue samples obtained from brain, heart, lungs, liver, kidney, and intestines. Treatment with 600 mg/kg dietary glucosylceramides for 4 weeks had no significant adverse effects, although a 6000 mg/kg dose was lethal (Tables 1,  2, 3) . The treatment selected was 300 mg/kg/day/mouse dietary glucosylceramides. NOD/SCID mice consistently tolerated the regimen of dietary glucosylceramides at 300 mg/kg/day for 14 days and no toxic reactions were observed (data not shown). The volumes of SCCKN xenograft tumors increased approximately 6.5-fold in the control group after 14 days on the cellulose solution (Fig. 2) . As shown in Fig. 2b , in the glucosylceramide treatment group, tumor volume decreased by approximately 40% after 14 days of treatment compared with that in the control group, suggesting anti-tumor activity of dietary glucosylceramides (Tables 2, 3 ).
Immunohistochemical and histological findings
Glucosylceramide and its metabolite ceramide have been shown to induce cell growth arrest and/or cell death [12, 17] . To examine the mechanisms underlying the antitumor activity of dietary glucosylceramides, we histopathologically examined tissue sections of subcutaneous tumors by staining with hematoxylin and eosin, TUNEL, and active/cleaved caspase-3. Hematoxylin and eosin stain revealed that in the dietary glucosylceramide group necrotic lesions tended to increase and mitogenic lesions in tumor tissue tended to decrease (Fig. 3a, b) . TUNEL staining was performed to determine whether dietary glucosylceramides induced apoptosis of tumor cells. TUNEL-positive cells were detected in tumor tissue sections obtained from the dietary glucosylceramide group (Fig. 3c, d, e, f) . The TUNEL index (percentage of TUNEL-positive cells) in tumor tissues was 0.42 ± 0.53% in the control group and 4.86 ± 1.96% in the dietary glucosylceramide group. Statistical analysis revealed a significant increase in the number of apoptotic cells in the dietary glucosylceramide group compared with the control group (Fig. 3g) .
Caspases are members of a cysteine protease family, and inactive precursors of the caspases are cleaved at Asp-X Slc:ddY mice were orally administered rice bran glucosylceramides at doses of 60, 600, or 6000 mg/kg/day. The mice were sacrificed after 28 days, and the tissues were evaluated histopathologically sites, thereby generating the active proteases. Activation of effector caspases such as caspase-3 leads to the execution of apoptosis. Immunohistochemical staining using antibodies selective for the 17-kDa cleaved/activated form of caspase-3 was performed to determine whether caspase-3 activation was involved in dietary glucosylceramide-induced apoptosis of tumor cells. Glucosylceramide treatment (Fig. 4b) elicited an increase in cleaved/active caspase-3 immunoreactivity in tumor tissues compared with control (Fig. 4a) . Cleaved/active caspase-3-positive cells constituted approximately 0.3% of total cell number in tumors from the vehicletreated animals (control), and glucosylceramide treatment significantly increased cleaved/active caspase-3-positive cells by 6.5% (Fig. 4c) . Slc:ddY mice were orally administered rice bran glucosylceramides at doses of 60 or 600 mg/kg/day for 28 days. The day after the final administration, blood samples from the inferior vena cava of mice using ether anesthesia were subjected to blood and biochemical tests
Discussion
We have demonstrated anti-tumor activity of dietary rice bran glucosylceramides in a SCCKN tumor xenograft model. Dietary glucosylceramides inhibited tumor growth by inducing apoptosis accompanied with caspase-3 activation (Figs. 2-4) . Thus, dietary glucosylceramides from rice bran are a new class of therapeutic agents for HNSCC. This is the first study to demonstrate the anti-tumor activity of dietary glucosylceramide on HNSCC in vivo. A number of glycosphingolipids have been shown to function as bioactive molecules [9, 21, 22] . This is the first to demonstrate inhibitory effects of glucosylceramides on HNSCC tumor growth in vivo. In other animal studies, feeding with b-glucosylceramides isolated from malt was reported not only to inhibit the growth of hepatoma cells implanted into nude mice but also to reduce the extent of metastasis of inoculated T-cell lymphoma [17] . Moreover, Inamine et al. [13] demonstrated in F344 rats that dietary glucosylceramides, isolated from rice bran, suppressed 1,2-dimethylhydrazine-induced formation of aberrant crypt foci with b-catenin accumulation during carcinogenesis. In the light of those findings, administration of dietary glucosylceramides is likely to inhibit tumor development including tumorigenesis, tumor growth, and metastasis.
A recent study showed that glucosylceramides induced apoptosis in cancer cells in vitro [14] . We showed that administration of dietary glucosylceramide induced caspase-3 activation and apoptotic cell death in xenografted tumor tissues (Figs. 3, 4) . Considering that caspase-3 is one of the key executioners in apoptosis, glucosylceramides per se might promote caspase-3-dependent apoptosis in HNSCC cells.
A metabolite of glucosylceramide, ceramide, has been identified as an apoptotic mediator [6, 8, 12, 16] . A ceramide precursor, sphingosine, is acylated with different chain-length fatty acids, generating a number of ceramide subspecies. Interestingly, mass spectrometric analysis revealed that only the C 18:0 -ceramide species was selectively down-regulated in tumor tissues from patients with HNSCC [23] . Moreover, this ceramide species was shown to inhibit HNSCC cell proliferation [24] . Defects in the accumulation of C 18:0 -ceramide (a, b) . In these experiments, each group contained eight mice. Tumor volume was measured twice a week as described in ''Materials and methods''. Data are mean ± SD (n = 8) at days 0, 7, and 14. Statistical analysis was performed as described in ''Materials and methods'' (c) might be clinically important in cell proliferation of HNSCC.
In this study, we demonstrated that administration of dietary glucosylceramide (C 18:0 -glucosylceramide) induced apoptotic cell death in the xenografted tumor tissues (Fig. 3) . Therefore it is possible that dietary C 18:0 -glucosylceramide is biologically converted to C 18:0 -ceramide and thereby inhibits the proliferation of or/and induces apoptosis in xenografted SCCKN cells. In the near future, whether dietary C 18:0 -glucosylceramide treatment increases ceramide subspecies in SCCKN cells will be determined. 9200 (a, b) . Cleaved/active caspase-3 staining in tumor tissues was scored as described in ''Materials and methods'' (c). The data shown (mean ± SD, n = 8) are the percentage of total cells with cleaved/ active capsase-3-positive staining Dietary glycosphingolipids are likely to stimulate tumor immunity. Besides cell death or growth arrest, administration of exogenous glycosphingolipids, for example b-glucosylceramide and a-galactosylceramide, has been shown to affect Th1/Th2-cells and cytokine profiles [25, 26] . Indeed, feeding malt glucosylceramides promoted tumor immunity by activating natural killer T lymphocytes in vivo, suppressing tumor growth in a tumor xenograft model [17] . Although natural killer T lymphocytes have been yet identified in NOD/SCID mice lacking functional B and T lymphocytes, the mice retain macrophage function, complement activity, function of dendritic cells, and natural killer cell activity. Those activities are important components of the innate immune system and very important in host defense against tumors. Dietary glucosylceramides may also stimulate tumor immunity to suppress tumor growth of HNSCC in NOD/SCID mice.
Our studies revealed the potential of dietary glucosylceramides as therapeutic agents for human HNSCC. We demonstrated the anti-tumor activity of dietary glucosylceramides against growth of HNSCC in a mouse xenograft model. The exact molecular mechanisms remain unknown. To fully understand the biological activity of dietary glucosylceramides, further studies are needed. Indeed, ongoing studies are focused on disclosing the absorption pathways and metabolism of dietary glucosylceramides in vivo, and the effects of dietary glucosylceramides on the immune system and on sphingolipid levels in the blood and tumor in a HNSCC xenograft model. It is believed that such extensive studies will facilitate the development of dietary rice bran glucosylceramides for human HNSCC.
